• HOME >
  • IBL News >
  • N-terminal fragment of titin in urine is useful as a diagnostic and clinical biomarker for patients with DMD. - new article -

IBL News

Product News

Product News2018/03/13
N-terminal fragment of titin in urine is useful as a diagnostic and clinical biomarker for patients with DMD. - new article -

Related Materials

A new article using our #27900 Titin N-Fragment Assay Kit - IBL has been published.

A New Article about Titin 

Muscular dystrophy is a group of inherited diseases that have necrosis / regeneration of skeletal muscle as main lesion.

It is said to be Duchenne muscular dystrophy (DMD) is the most common one in muscular dystrophy.

Once DMD patients have muscle damage, it is known that titin is digested by proteolytic enzymes such as calpain and matrix metalloprotease, and fragments of titin are secreted into the urine. 

In this study, 158 samples (113 DMD patients, 36 BMD (Becker muscular dystrophy) patients and nine healthy children) were collected and measured the concentration of titin N-Fragment in urine using #27900 Titin N-Fragment Assay Kit – IBL.

As a result, the concentration was 965.8 ± 1011.9 pmol / mg Cr in patients with DMD.
This was nearly 700-fold higher than healthy children.
In BMD patients, it was 171.2 ± 272.7 pmol / mg Cr, which was significantly lower than that of patients with DMD and significantly higher than that of healthy children. 

Urinary concentration of titin N-fragment correlated significantly with serum creatine kinase concentration, the best-known biomarker of DMD. 

From these results it is suggested that the N-terminal fragment of titin in urine has potential as a diagnostic and clinical biomarker for DMD.


Please refer to the article for further information.

It would be great if our products help your research.

Please feel free to contact us.

Immuno-Biological Laboratories Co., Ltd.
Diagnostic Research Reagent Division
Sales Support
TEL: +81-274-50-8666
Email: do-ibl@ibl-japan.co.jp